---
document_datetime: 2026-01-16 13:53:35
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/intuniv-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: intuniv-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8196288
conversion_datetime: 2026-01-17 12:54:54.691993
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Intuniv

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 0F 1 issued on   | Commission Decision Issued 1F 2 / amended on   | Product Information affected 2F 3   | Summary   |
|----------------------|------------------------------------|----------------------------------------|------------------------------------------------|-------------------------------------|-----------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 11/12/2025                             |                                                | SmPC and PL                         |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000269598                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4, 4.8, and 4.9 of the SmPC in order to add Electrocardiogram QT prolonged to the list of adverse drug reactions (ADRs) with frequency uncommon, and update the warnings and description of overdose, based on post-authorisation, non- clinical and clinical data. In addition, the MAH took the opportunity to introduce editorial changes to the PI.   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000310753 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF                   | 07/11/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|